Thousand Oaks-based biotech giant Amgen said July 15 that it will have a new chief financial officer effective Sept. 1. Jonathan Peacock will replace Michael Kelly, who has served as acting CFO since May.
Peacock, 52, comes to Amgen after five years as CFO of healthcare products company Novartis Pharmaceutical AG.
“I am delighted to have a leader of Jonathan’s talent, vision and international experience join Amgen at a time when we are expanding globally,” Amgen Chairman and CEO Kevin Sharer said in a news release.
Peacock was previously a partner at consulting firm McKinsey and Co., where he was part of the team leading the European corporate finance practices from the company’s Amsterdam, Zurich and London offices. Prior to that he was a partner at Price Waterhouse in New York and London.
Peacock’s annual base salary will be $800,000 plus stocks and options. He will also receive a $1 million sign-on bonus as well as a relocation package of up to $400,000, according to regulatory filings.
Kelly, the outgoing Amgen CFO, will relocate to the company’s offices in Zug, Switzerland to serve as the company’s vice president of international finance, a non-executive role.